Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Summary

This phase Ib/II trial studies the best dose of glembatumumab vedotin when giving together with nivolumab and ipilimumab in treating patients with solid tumor that has spread to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as glembatumumab vedotin, nivolumab, and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2018-04-20

Primary completion

2018-04-20

Completion

2018-04-20

Outcome

Outcome not reported

Stopped: “The study itself was Disapproved on 04/20/2018 and will not be moving forward.”

Drugs

Indications